C WorldWide Group Holding A S increased its position in shares of Dermira, Inc. (NASDAQ:DERM) by 46.0% during the second quarter, Holdings Channel reports. The firm owned 120,815 shares of the biopharmaceutical company’s stock after buying an additional 38,069 shares during the period. C WorldWide Group Holding A S’s holdings in Dermira were worth $3,521,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. increased its stake in Dermira by 4,816.7% in the first quarter. BlackRock Inc. now owns 3,392,848 shares of the biopharmaceutical company’s stock worth $115,729,000 after buying an additional 3,323,841 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in Dermira by 6.8% in the first quarter. TimesSquare Capital Management LLC now owns 2,588,661 shares of the biopharmaceutical company’s stock worth $88,299,000 after buying an additional 164,950 shares in the last quarter. Vanguard Group Inc. increased its stake in Dermira by 20.7% in the first quarter. Vanguard Group Inc. now owns 1,272,700 shares of the biopharmaceutical company’s stock worth $43,412,000 after buying an additional 217,943 shares in the last quarter. Jana Partners LLC increased its stake in Dermira by 171.0% in the first quarter. Jana Partners LLC now owns 655,252 shares of the biopharmaceutical company’s stock worth $22,351,000 after buying an additional 413,442 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in Dermira during the first quarter worth about $20,296,000. Institutional investors and hedge funds own 84.57% of the company’s stock.

Shares of Dermira, Inc. (DERM) opened at 23.25 on Friday. The company’s market cap is $966.99 million. The stock’s 50 day moving average is $28.06 and its 200-day moving average is $30.67. Dermira, Inc. has a one year low of $21.35 and a one year high of $38.75.

Dermira (NASDAQ:DERM) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.04. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1 million. Equities research analysts forecast that Dermira, Inc. will post ($4.17) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/12/c-worldwide-group-holding-a-s-increases-position-in-dermira-inc-derm.html.

A number of research firms have issued reports on DERM. BidaskClub downgraded shares of Dermira from a “sell” rating to a “strong sell” rating in a report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price objective on shares of Dermira in a report on Tuesday, July 18th. Cantor Fitzgerald began coverage on shares of Dermira in a report on Thursday, June 22nd. They issued an “overweight” rating and a $45.00 price objective for the company. Evercore ISI began coverage on shares of Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Five research analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $43.80.

In other news, SVP Christopher M. Griffith sold 1,312 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $27.07, for a total value of $35,515.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas G. Wiggans sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,812 shares of company stock valued at $482,231. 13.30% of the stock is currently owned by company insiders.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira, Inc. (NASDAQ:DERM).

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.